ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy and CSO Dr Sébastien Goudreau talked with Proactive's Stephen Gunnion about the company’s latest milestone — the filing of a new patent application for its lead drug candidate P140, described as the world’s first “immunormaliser” for treating autoimmune diseases. This patent filing marks a major development in the company’s mission to bring P140 to market, with McCarthy describing it as a “truly groundbreaking” innovation and part of ImmuPharma’s 2025 plan to deliver commercial outcomes. The filing is expected to support licensing discussions, offering potential partners a new 20-year exclusivity window. Goudreau provided scientific context, explaining the work his team has carried out since 2021 to understand the shortfalls of the previous Phase III trial. “We have succeeded… to identify the responder to P140,” he said, referring to patients with a newly defined immune disorder, Type M. The team also developed a diagnostic test to detect “super responders,” which is now part of the new patent. The patent includes three key discoveries: confirmation of P140’s mechanism in human biology, the identification of the Type M immune disorder, and the development of the companion diagnostic. Goudreau emphasised that P140 acts as an “immune normaliser,” rather than a suppressor — a unique approach with potential to improve treatment outcomes and reduce side effects. McCarthy added that this patent strengthens ImmuPharma’s commercial position, providing leverage in current licensing talks and opening access to a therapeutic market worth over $100 billion and a diagnostics market valued at around $10 billion. For more exclusive interviews and insights, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications so you never miss an update. #ImmuPharma #P140 #AutoimmuneDiseases #BiotechNews #PharmaInnovation #ClinicalTrials #DrugDevelopment #Immunotherapy #HealthcareTech #BiotechInvesting #PatentNews #Diagnostics #LifeSciences #InvestorUpdates #ProactiveInvestors